Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Bank of America Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target increased by Bank of America from $302.00 to $325.00 in a report published on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

ALNY has been the topic of several other research reports. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Royal Bank of Canada restated an “outperform” rating and issued a $310.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Finally, HC Wainwright boosted their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $310.22.

Alnylam Pharmaceuticals Stock Up 11.8 %

Alnylam Pharmaceuticals stock opened at $283.34 on Friday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a 50-day simple moving average of $257.16 and a 200-day simple moving average of $259.74. The company has a market capitalization of $36.68 billion, a P/E ratio of -130.57 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,548 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,017,271.63. This represents a 11.44 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 71,234 shares of company stock worth $19,958,097. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Allworth Financial LP increased its stake in Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 38 shares in the last quarter. Investment Management Corp of Ontario boosted its stake in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock worth $1,670,000 after buying an additional 40 shares during the last quarter. Nixon Peabody Trust Co. grew its stake in Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock valued at $540,000 after purchasing an additional 43 shares in the last quarter. Brevan Howard Capital Management LP raised its position in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 44 shares in the last quarter. Finally, IFP Advisors Inc raised its holdings in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 47 shares during the period. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.